AU700481B2 - Compounds for the suppression of HIV TAT transactivation - Google Patents

Compounds for the suppression of HIV TAT transactivation Download PDF

Info

Publication number
AU700481B2
AU700481B2 AU36339/95A AU3633995A AU700481B2 AU 700481 B2 AU700481 B2 AU 700481B2 AU 36339/95 A AU36339/95 A AU 36339/95A AU 3633995 A AU3633995 A AU 3633995A AU 700481 B2 AU700481 B2 AU 700481B2
Authority
AU
Australia
Prior art keywords
compound
cell
tat
hiv
seap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU36339/95A
Other languages
English (en)
Other versions
AU3633995A (en
Inventor
John N. Gnabre
Ru Chih Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU3633995A publication Critical patent/AU3633995A/en
Application granted granted Critical
Publication of AU700481B2 publication Critical patent/AU700481B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/017—Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU36339/95A 1994-09-30 1995-09-22 Compounds for the suppression of HIV TAT transactivation Ceased AU700481B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US316341 1994-09-30
US08/316,341 US6365787B1 (en) 1994-09-30 1994-09-30 Compounds for the suppression of HIV TAT transactivation
PCT/US1995/011779 WO1996010549A1 (en) 1994-09-30 1995-09-22 Compounds for the suppression of hiv tat transactivation

Publications (2)

Publication Number Publication Date
AU3633995A AU3633995A (en) 1996-04-26
AU700481B2 true AU700481B2 (en) 1999-01-07

Family

ID=23228649

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36339/95A Ceased AU700481B2 (en) 1994-09-30 1995-09-22 Compounds for the suppression of HIV TAT transactivation

Country Status (10)

Country Link
US (4) US6365787B1 (enExample)
EP (1) EP0783474B1 (enExample)
JP (2) JP3966900B2 (enExample)
CN (2) CN100413835C (enExample)
AT (1) ATE403635T1 (enExample)
AU (1) AU700481B2 (enExample)
CA (1) CA2200991C (enExample)
DE (1) DE69535804D1 (enExample)
ES (1) ES2312168T3 (enExample)
WO (1) WO1996010549A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
WO1999017609A1 (en) * 1997-10-07 1999-04-15 Larreacorp, Ltd. Nontoxic extract of larrea tridentata and method of making the same
US6608108B2 (en) 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US20030219407A1 (en) 2002-05-15 2003-11-27 The Regents Of The University Of California RNA silencing in animals as an antiviral defense
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
WO2004112695A2 (en) * 2003-05-20 2004-12-29 Erimos Pharmaceutical Llc Methods and compositions for delivery of catecholic butanes for treatment of obesity
US7728036B2 (en) 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
CN100440843C (zh) * 2004-05-12 2008-12-03 华为技术有限公司 一种环网及其业务实现方法
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
US20080096967A1 (en) * 2005-01-27 2008-04-24 Erimos Pharmaceuticals Llc Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals
CN101150956B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 用于注射入动物的包括ndga化合物的儿茶酚丁烷配方
EP1996174A2 (en) * 2006-02-23 2008-12-03 Erimos Pharmaceuticals LLC Methods of treating influenza viral infections
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
EP2076252B1 (en) * 2006-10-02 2014-04-02 Erimos Pharmaceuticals LLC Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
MX343303B (es) * 2007-05-11 2016-11-01 Convatec Tech Inc * Aparato de ostomia.
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
MX2011004824A (es) * 2008-11-07 2012-01-12 Triact Therapeutics Inc Uso de derivados de butano catecólico en terapia contra el cáncer.
WO2012096934A2 (en) * 2011-01-10 2012-07-19 The Scripps Research Institute Inhibitors of retroviral replication
WO2013116821A1 (en) * 2012-02-03 2013-08-08 The Johns Hopkins University Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer
SG11201500397XA (en) * 2012-07-18 2015-03-30 Univ Johns Hopkins Methods for inhibition of bnip3 and prevention and treatment of ischemia reperfusion injury by tetra-o-methyl nordihydroguaiaretic acid
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
EP3044593A4 (en) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003026A1 (en) * 1986-10-28 1988-05-05 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
AU7250294A (en) * 1993-06-23 1995-01-17 Chemex Pharmaceuticals Inc. Treatment of multidrug resistant diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US5276060A (en) * 1979-06-19 1994-01-04 Block/Chemex, G.P. Methods of treating tumors with compositions of catecholic butanes
DE3009542A1 (de) 1980-03-13 1981-09-24 Henkel KGaA, 4000 Düsseldorf Desodorierende kosmetische zusammensetzungen
US4774229A (en) 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
FR2632956B2 (fr) * 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
US5559149A (en) 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
US5195965A (en) * 1991-03-07 1993-03-23 Shantha Totada R Method and apparatus for localized treatment of human viral infections and cancers
US5646186A (en) 1994-05-17 1997-07-08 Johnson & Johnson Consumer Products, Inc. Retinoid composition
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US6071949A (en) 1995-03-14 2000-06-06 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5837252A (en) * 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
US5827898A (en) 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
AU736587B2 (en) 1996-11-20 2001-08-02 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003026A1 (en) * 1986-10-28 1988-05-05 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
AU7250294A (en) * 1993-06-23 1995-01-17 Chemex Pharmaceuticals Inc. Treatment of multidrug resistant diseases

Also Published As

Publication number Publication date
ATE403635T1 (de) 2008-08-15
CN1762951A (zh) 2006-04-26
US5663209A (en) 1997-09-02
WO1996010549A1 (en) 1996-04-11
JP2006273869A (ja) 2006-10-12
EP0783474A4 (enExample) 1997-08-27
CA2200991A1 (en) 1996-04-11
USRE40246E1 (en) 2008-04-15
CN1162301A (zh) 1997-10-15
US6291524B1 (en) 2001-09-18
EP0783474A1 (en) 1997-07-16
CN1211335C (zh) 2005-07-20
CA2200991C (en) 2007-07-10
JPH10509421A (ja) 1998-09-14
ES2312168T3 (es) 2009-02-16
US6365787B1 (en) 2002-04-02
JP3966900B2 (ja) 2007-08-29
EP0783474B1 (en) 2008-08-06
CN100413835C (zh) 2008-08-27
DE69535804D1 (de) 2008-09-18
AU3633995A (en) 1996-04-26

Similar Documents

Publication Publication Date Title
AU700481B2 (en) Compounds for the suppression of HIV TAT transactivation
WO1996010549A9 (en) Compounds for the suppression of hiv tat transactivation
Gnabre et al. Isolation of anti-HIV-1 lignans from Larrea tridentata by counter-current chromatography
US6844013B2 (en) Methods of stimulating the immune system
KR101567633B1 (ko) 감귤 미성숙과 추출물, 또는 시네프린 또는 이의 염을 유효성분으로 포함하는 염증성 피부질환 치료 또는 예방용 조성물
Pal A review on Cyperus rotundus as a tremendous source of pharmacologically active herbal medicine
US6998394B2 (en) Process for isolating physalins from plants and pharmaceutical compositions containing physalins
US6428823B1 (en) Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L
US5989555A (en) Extracts of Larrea tridentata having antiviral activity and their use for treating viral infections
US20090142421A1 (en) Active fraction of a polar solvent extract from the latex of euphorbiaceae plants
CA1303052C (en) Avarone and avarol pharmaceutical compositions, and process
AU750628B2 (en) Anti-cancer compounds-II
AU2001256653B2 (en) Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L.
AU4811601A (en) Anti-cancer compounds-I
WO1994027593A1 (en) Use of 12-deoxyphorbol 13-monoesters for inhibiting neoplasia and tumor promotion
AU4811701A (en) Anti-cancer compounds-III
AU2001256653A1 (en) Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L.
JPH0441499A (ja) 発癌予防剤